The company received FDA clearance for its MiniMed Go smart insulin system and its Altaviva urinary incontinence implant. It announced a strategic partnership with Precision Neuroscience to co-develop an integrated brain surgery imaging system combining neural interface technology with its surgical navigation platform. Analysts have slightly increased its fair value estimate following Q2 results, citing improved earnings quality from higher-margin products. Management highlighted multi-billion dollar opportunities in key markets like pulsed field ablation and renal denervation.